RA
ZVSAW

RiverPark Advisors’s ZyVersa Therapeutics, Inc. Warrants ZVSAW Stock Holding History

RiverPark Advisors’s Portfolio ZVSAW Stock Details ZVSAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-525,000
Closed -$90K – 209
2022
Q1 		$90K Buy
+525,000
New +$106K 0.02% 159

Other funds holding ZVSAW

MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
EFI
EHP Funds Inc Toronto, Canada $43.6M AUM 69.08% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $1B AUM 29.68% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $1.14B AUM 6.91% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

RiverPark Advisors's ZVSAW Position: Q2 2022 in Review

RiverPark Advisors sold out of ZyVersa Therapeutics, Inc. Warrants (ZVSAW) in Q2 2022, closing a stake of 525,000 shares — an estimated $90K sold.

RiverPark Advisors first reported a position in ZVSAW in Q1 2022 and held it in 1 quarter. The position peaked at $90K in Q1 2022. 16 funds tracked by Wall St. Rank hold ZVSAW as of Q2 2022.

  • RiverPark Advisors reported no remaining ZyVersa Therapeutics, Inc. Warrants position as of Q2 2022 after selling out during the quarter.
  • RiverPark Advisors sold 525,000 ZyVersa Therapeutics, Inc. Warrants shares in Q2 2022, an estimated $90K.
  • RiverPark Advisors first reported a position in ZyVersa Therapeutics, Inc. Warrants in Q1 2022 and held it in 1 quarter.
  • RiverPark Advisors's ZyVersa Therapeutics, Inc. Warrants position peaked at $90K in Q1 2022.
  • 16 funds tracked by Wall St. Rank held ZyVersa Therapeutics, Inc. Warrants as of Q2 2022.

Based on RiverPark Advisors's 13F filing for Q2 2022, filed 15 Aug 2022.